Clinical Trials Directory

Trials / Unknown

UnknownNCT03220386

Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
Charite University, Berlin, Germany · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

The study EPICS-6 consists of three study phases. Emergency Department patients are screened for nasal and pharyngeal colonisation with Methicillin sensitive and Methicillin resistant Staphylococcus aureus (MSSA/MRSA) using a point-of-care (POC)-PCR-testing method (cobas®LIAT®-System, Roche Molecular Systems Inc.) The first aim of this study is to describe the prevalence of MSSA/MRSA-colonisation in a routine cohort of Emergency Department patients. The second aim is to determine the impact of POC-guided decolonisation as compared to conventional laboratory testing on in-hospital infection rates with MSSA/MRSA in a pre-post-comparison study.

Detailed description

The study EPICS-6 consists of three study phases. In phase one the novel POC-PCR-testing method for MSSA/MRSA-proof (cobas®LIAT®-System, Roche Molecular Systems Inc.) is technically established and integrated in Emergency Department procedures. After evaluation of processes and sample handling the second phase of this study assesses the prevalence of positive MSSA/MRSA-POC-testing in the general ED-population and in different risk groups. Based on the results of the previous study phases, the final phase comprises an interventional pre-post-comparison study. The interventional study assesses the impact of POC-result guided early decolonisation of MSSA/MRSA-colonized patients on in-hospital infection rates with MSSA/MRSA.

Conditions

Interventions

TypeNameDescription
OTHERDecolonization by nasal Octinidin treatment and skin washingsPatients receive nasal Octinidin treatment and skin washings for five consecutive days

Timeline

Start date
2017-05-01
Primary completion
2018-08-01
Completion
2018-08-01
First posted
2017-07-18
Last updated
2017-07-18

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT03220386. Inclusion in this directory is not an endorsement.